Tag:
Open source R&D
Latest Headlines
Latest Headlines
Roche follows GSK in move to unlock its data vault on drugs
GlaxoSmithKline encountered some stiff industry headwinds when it pledged to open up its data vault to outside investigators. But as of today it has a high-profile convert on its side. The biopharma giant Roche has agreed to follow in GSK's footsteps, saying that it will work with an independent group which will be charged with sorting out and approving requests for access to anonymized clinical trial data for all approved products. If regulators can't provide the data, says Roche, then the company will make it available.
A new wave of biotechs takes shape in the U.K.
Over the past few days I've met with dozens of people in the U.K.'s biotech industry, getting a crash course on the state of affairs here while getting a chance to offer a few opinions of my own on global drug development trends at a One Nucleus gathering at Canada House. More >>
Expect bold moves in the biopharma industry in 2013
Don't be fooled by the overflow of news on stock swings and megabucks involved in biotech; many people--and I would guess most--become enamored with this industry because of the promise of transforming scientific discoveries into new therapies. Bank on 2013 being a year when real innovators in life sciences with bold ideas look like smart businesspeople too. Read more >>
Pfizer ramps up work with academics and biotech startups
Now more than a year into an R&D experiment to foster closer ties with academia, Pfizer ($PFE) has won over some top researchers with an open-arms approach to advancing science from labs to the clinic.
Gamers illustrate potential of new crowd-sourcing protein work
One of the most intriguing new developments in the drug discovery field has been the recruitment of gamers into the puzzling business of protein folding. Now an initial foray into simple puzzle
Novo crafts fast-track R&D model for new diabetes drug unit
Novo Nordisk ( $NVO ) is setting up a new R&D center in Seattle that aims at reengineering the model for early-stage drug work and speeding up development in the diabetes field. Under the direction
R&D execs continue the global search for efficiency, open innovation
Throughout 2011 we've seen a continuation of an intense reengineering of the development process at a slate of Big Pharma companies. Pfizer ( $PFE ), of course, grabbed the biggest headlines as it
Sanford-Burnham joins Pfizer's growing list of translational med partners
Sanford-Burnham Medical Research Institute in La Jolla, CA has joined the growing list of scientific groups to team up with Pfizer on its new effort to spur translational medicine programs for
Lilly uses web system to find a few diamonds in the rough
Open source, collaborative discovery models are all the rage these days. Researchers interested in vetting their compound's potential while looking for the opportunity to hook up with a pharma giant
Bayer will cap R&D budget at $4.1B
With R&D expenses expected to surge 13 percent this year at Bayer, Germany's largest drug company, CEO Marijn Dekkers is telling reporters that he plans to make sure the budget item flatlines at
